Management of inappropriate sinus tachycardia with ivabradine in a renal transplant recipient

Goyal, Vipin; Godara, Suraj; Sadasukhi, Trilok Chandra; Gupta, Hoti Lal

doi:10.5582/ddt.2014.01023

Cited by 8 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IST can be observed in ESRD patients and renal transplant recipients. Ivabradine can be used as an alternative to beta-blockers and calcium channel blockers for management of IST when these agents are not tolerated or an overdose is to be avoided (29).…”

Section: Ivabradine and Chronic Kidney Diseasementioning

confidence: 99%

Ivabradine, Heart Failure and Chronic Kidney Disease

Lullo

Bellasi

Russo

et al. 2015

Nephrology @ Point of Care

View full text Add to dashboard Cite

The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially in Western countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients' outcomes and quality of life. The latest clinical trials to evaluate ivabradine's efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients.

show abstract

Section: Ivabradine and Chronic Kidney Diseasementioning

confidence: 99%

Ivabradine, Heart Failure and Chronic Kidney Disease

Lullo

Bellasi

Russo

et al. 2015

Nephrology @ Point of Care

View full text Add to dashboard Cite

show abstract

“…12–14 Other ivabradine trials evaluated its effects on the following: left ventricular remodeling in a perfused heart after myocardial infarction, cardiogenic shock, as a bridge agent in atrial tachycardia, for prevention of dobutamine-induced increased heart rate in patients with heart failure, tachycardia in a renal transplant patient, in a patient with nemaline myopathy and heart failure, and with concurrent lisinopril and a multivitamin supplement for the treatment of anthracycline-induced severe cardiotoxicity. 15–21…”

Section: Indicationsmentioning

confidence: 99%

Ivadradine

2015

View full text Add to dashboard Cite

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The October 2015 monograph topics are sacubitril/valsartan, daclatasvir, sonidegib, alirocumab, and sodium zirconium cyclosilicate. The Safety MUE is on sacubitril/valsartan.

show abstract

Ivabradine: A Review of Labeled and Off-Label Uses

Oliphant

Owens

Bolorunduro

et al. 2016

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

Ivabradine is a unique medication recently approved in the USA for the treatment of select heart failure patients. It was first approved for use in several countries around the world over a decade ago as an anti-anginal agent, with subsequent approval for use in heart failure patients. Since ivabradine has selective activity blocking the I f currents in the sinus node, it can reduce heart rate without appreciable effects on blood pressure. Given this heart-rate-specific effect, it has been investigated in many off-label indications as an alternative to traditional heart-rate-reducing medications such as beta blockers and calcium channel blockers. We conducted searches of PubMed and Google Scholar for ivabradine, heart failure, HFrEF, HFpEF, angina, coronary artery disease, inappropriate sinus tachycardia, postural orthostatic hypotension, coronary computed tomography angiography and atrial fibrillation. We reviewed and included studies, case reports, and case series published between 1980 and June 2016 if they provided information relevant to the practicing clinician. In many cases, larger clinical trials are needed to solidify the benefit of ivabradine, although studies indicate benefit in most therapeutic areas explored to date. The purpose of this paper is to review the current labeled and off-label uses of ivabradine, with a focus on clinical trial data.

show abstract

Management of inappropriate sinus tachycardia with ivabradine in a renal transplant recipient

Cited by 8 publications

References 6 publications

Ivabradine, Heart Failure and Chronic Kidney Disease

Ivabradine, Heart Failure and Chronic Kidney Disease

Ivadradine

Ivabradine: A Review of Labeled and Off-Label Uses

Contact Info

Product

Resources

About